Browsing by Author "Johnson, Eli"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Open Access Characteristics of patients who return to work after undergoing surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study.(Journal of neurosurgery. Spine, 2023-05) Bergin, Stephen M; Michalopoulos, Giorgos D; Shaffrey, Christopher I; Gottfried, Oren N; Johnson, Eli; Bisson, Erica F; Wang, Michael Y; Knightly, John J; Virk, Michael S; Tumialán, Luis M; Turner, Jay D; Upadhyaya, Cheerag D; Shaffrey, Mark E; Park, Paul; Foley, Kevin T; Coric, Domagoj; Slotkin, Jonathan R; Potts, Eric A; Chou, Dean; Fu, Kai-Ming G; Haid, Regis W; Asher, Anthony L; Bydon, Mohamad; Mummaneni, Praveen V; Than, Khoi DObjective
Return to work (RTW) is an important surgical outcome for patients who are employed, yet a significant number of patients with cervical spondylotic myelopathy (CSM) who are employed undergo cervical spine surgery and fail to RTW. In this study, the authors investigated factors associated with failure to RTW in the CSM population who underwent cervical spine surgery and who were considered to have a good surgical outcome yet failed to RTW.Methods
This study retrospectively analyzed prospectively collected data from the cervical myelopathy module of a national spine registry, the Quality Outcomes Database. The CSM data set of the Quality Outcomes Database was queried for patients who were employed at the time of surgery and planned to RTW postoperatively. Distinct multivariable logistic regression models were fitted with 3-month RTW as an outcome for the overall population to identify risk factors for failure to RTW. Good outcomes were defined as patients who had no adverse events (readmissions or complications), who had achieved 30% improvement in Neck Disability Index score, and who were satisfied (North American Spine Society satisfaction score of 1 or 2) at 3 months postsurgery.Results
Of the 409 patients who underwent surgery, 80% (n = 327) did RTW at 3 months after surgery. At 3 months, 56.9% of patients met the criteria for a good surgical outcome, and patients with a good outcome were more likely to RTW (88.1% vs 69.2%, p < 0.01). Of patients with a good outcome, 11.9% failed to RTW at 3 months. Risk factors for failing to RTW despite a good outcome included preoperative short-term disability or leave status (OR 3.03 [95% CI 1.66-7.90], p = 0.02); a higher baseline Neck Disability Index score (OR 1.41 [95% CI 1.09-1.84], p < 0.01); and higher neck pain score at 3 months postoperatively (OR 0.81 [95% CI 0.66-0.99], p = 0.04).Conclusions
Most patients with CSM who undergo spine surgery reenter the workforce within 3 months from surgery, with RTW rates being higher among patients who experience good outcomes. Among patients with good outcomes who were employed, failure to RTW was associated with being on preoperative short-term disability or leave status prior to surgery as well as higher neck pain scores at baseline and at 3 months postoperatively.Item Open Access Gene Therapy and Spinal Fusion: Systematic Review and Meta-Analysis of the Available Data.(World neurosurgery, 2024-06) Cottrill, Ethan; Pennington, Zach; Sattah, Nathan; Jing, Crystal; Salven, Dave; Johnson, Eli; Downey, Max; Varghese, Shyni; Rocos, Brett; Richardson, WilliamObjective
To analyze the extant literature describing the application of gene therapy to spinal fusion.Methods
A systematic review of the English-language literature was performed. The search query was designed to include all published studies examining gene therapy approaches to promote spinal fusion. Approaches were classified as ex vivo (delivery of genetically modified cells) or in vivo (delivery of growth factors via vectors). The primary endpoint was fusion rate. Random effects meta-analyses were performed to calculate the overall odds ratio (OR) of fusion using a gene therapy approach and overall fusion rate. Subgroup analyses of fusion rate were also performed for each gene therapy approach.Results
Of 1179 results, 35 articles met criteria for inclusion (all preclinical), of which 26 utilized ex vivo approaches and 9 utilized in vivo approaches. Twenty-seven articles (431 animals) were included in the meta-analysis. Gene therapy use was associated with significantly higher fusion rates (OR 77; 95% confidence interval {CI}: [31, 192]; P < 0.001); ex vivo strategies had a greater effect (OR 136) relative to in vivo strategies (OR 18) (P = 0.017). The overall fusion rate using a gene therapy approach was 80% (95% CI: [62%, 93%]; P < 0.001); overall fusion rates were significantly higher in subjects treated with ex vivo compared to in vivo strategies (90% vs. 42%; P = 0.011). For both ex vivo and in vivo approaches, the effect of gene therapy on fusion was independent of animal model.Conclusions
Gene therapy may augment spinal fusion; however, future investigation in clinical populations is necessary.Item Open Access Perioperative Blindness in Spine Surgery: A Scoping Literature Review.(Journal of clinical medicine, 2024-02) Sperber, Jacob; Owolo, Edwin; Zachem, Tanner J; Bishop, Brandon; Johnson, Eli; Lad, Eleonora M; Goodwin, C RoryPerioperative vision loss (POVL) is a devastating surgical complication that impacts both the recovery from surgery and quality of life, most commonly occurring after spine surgery. With rates of spine surgery dramatically increasing, the prevalence of POVL will increase proportionately. This scoping review aims to aggregate the literature pertinent to POVL in spine surgery and consolidate recommendations and preventative measures to reduce the risk of POVL. There are several causes of POVL, and the main contribution following spine surgery is ischemic optic neuropathy (ION). Vision loss often manifests immediately following surgery and is irreversible and severe. Diffusion weighted imaging has recently surfaced as a diagnostic tool to identify ION. There are no effective treatments; therefore, risk stratification for counseling and prevention are vital. Patients undergoing prone surgery of long duration and/or with significant expected blood loss are at greatest risk. Future research is necessary to develop effective treatments.